Plegridy

RSS

peginterferon beta-1a

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR) for Plegridy. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Plegridy.

For practical information about using Plegridy, patients should read the package leaflet or contact their doctor or pharmacist.

This EPAR was last updated on 26/11/2018

Authorisation details

Product details
Name
Plegridy
Agency product number
EMEA/H/C/002827
Active substance
peginterferon beta-1a
International non-proprietary name (INN) or common name
peginterferon beta-1a
Therapeutic area (MeSH)
Multiple Sclerosis
Anatomical therapeutic chemical (ATC) code
L03AB13
Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring.

Publication details
Marketing-authorisation holder
Biogen Netherlands B.V.
Revision
15
Date of issue of marketing authorisation valid throughout the European Union
17/07/2014
Contact address

Prins Mauritslaan 13
1171 LP Badhoevedorp
The Netherlands

Product information

04/10/2018 Plegridy - EMEA/H/C/002827 - II/0046

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Immunostimulants

Therapeutic indication

Treatment of relapsing remitting multiple sclerosis in adult patients.

Assessment history

How useful was this page?

Add your rating